## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Group Art Unit: Not yet assigned
Ashkenazi et al.	Examiner: Not yet assigned
Serial No.: Not yet assigned	
Filed: Herewith	
For: Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same	

## PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Prior to substantive examination of the above captioned patent application (which is filed herewith), and for calculation of the proper filing fee, Applicants respectfully request that the following amendments be entered.

Filed: Herewith

## In the claims:

Please cancel Claims 1-38 without prejudice or disclaimer.

Please add new Claims 39-51 as follows.

- --39. (New) An isolated polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.
- 40. (New) The isolated polypeptide of Claim 39 having at least 85% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.

Filed: Herewith

41. (New) The isolated polypeptide of Claim 39 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.
- 42. (New) The isolated polypeptide of Claim 39 having at least 95% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.

Filed: Herewith

43. (New) The isolated polypeptide of Claim 39 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.
  - 44. (New) An isolated polypeptide comprising:
  - (a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.
- 45 (New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4).

Filed: Herewith

(New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide.

(New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4).

(New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:4), lacking its associated signal peptide.

(New) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.

50. (New) A chimeric polypeptide comprising a polypeptide according to Claim 39 fused to a heterologous polypeptide.

51. (New) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.--

Filed: Herewith

PATENT TRADEMARK OFFICE

Applicants respectfully request entry of these new claims for prosecution in this application. The Examiner is invited to contact the undersigned at (650) 225-4461 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

Mark T. Kresnak, Ph.D.

Reg. No. 42,767

Telephone: (650) 225-4461

-6-